CYBIN INC (CYBN)

Company Profile

Cybin Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. The company has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Company Info

CYBIN INC

100 King Street West, Suite 5600

TORONTO ONTARIO

P: 19087648385

CEO: Doug Drysdale

Employees: 50

Website: https://www.cybin.com